Research programme: monoclonal antibody therapeutics - ImmuneXcite TechnologyAlternative Names: mAbXcite antibodies; mAbXcite-cetuximab; mAbXcite-trastuzumab
Latest Information Update: 07 Apr 2016
At a glance
- Originator ImmuneXcite
- Class Monoclonal antibodies; Recombinant fusion proteins
- Mechanism of Action Immunostimulants
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Preclinical Breast cancer; Colorectal cancer